3/A//SEC Filing
Framework Ventures Management LLC 3/A
Accession 0001829126-25-008354
CIK 0001389545other
Filed
Oct 21, 8:00 PM ET
Accepted
Oct 22, 9:22 PM ET
Size
31.1 KB
Accession
0001829126-25-008354
Insider Transaction Report
Form 3/AAmended
Framework Ventures IV GP LLC
10% Owner
Holdings
Series D Non-Voting Convertible Preferred Stock
Exercise: $0.00From: 2025-10-16→ Common Stock (1,164,117 underlying)
Framework Ventures IV L.P.
10% Owner
Holdings
Series D Non-Voting Convertible Preferred Stock
Exercise: $0.00From: 2025-10-16→ Common Stock (1,164,117 underlying)
Framework Ventures Management LLC
10% Owner
Holdings
Series D Non-Voting Convertible Preferred Stock
Exercise: $0.00From: 2025-10-16→ Common Stock (1,164,117 underlying)
Spencer Vance
10% Owner
Holdings
Series D Non-Voting Convertible Preferred Stock
Exercise: $0.00From: 2025-10-16→ Common Stock (1,164,117 underlying)
Anderson Michael Ernest
10% Owner
Holdings
Series D Non-Voting Convertible Preferred Stock
Exercise: $0.00From: 2025-10-16→ Common Stock (1,164,117 underlying)
Footnotes (3)
- [F1]On October 9, 2025, Framework Ventures IV L.P. ("Framework LP"), David Lazar (the "Seller") and certain other investors entered into a securities purchase agreement pursuant to which Framework LP purchased all of Seller's rights, title and interest in (i) 220,663 shares of the Issuer's Series D Non-Voting Convertible Preferred Stock, par value $0.01 per share (the "Series D Preferred Stock"), which is convertible into a maximum of 1,164,117 shares of the Issuer's Common Stock and (ii) the rights and obligation to purchase 134,375 shares of the Issuer's Series E Non-Voting Convertible Preferred Stock, par value $0.01 per share (the "Series E Preferred Stock").
- [F2]Following stockholder approval of proposals 5 and 9 set forth in the Issuer's Definitive Proxy Statement on Schedule 14A, filed by the Issuer with the Securities and Exchange Commission on September 23, 2025, at the Issuer's annual meeting on October 16, 2025 (the "Meeting"), (i) each share of Series D Preferred Stock will automatically convert into 160 shares of common stock at the option of the holder or within three business days of the Meeting, and (ii) the Issuer will issue the Series E Preferred Stock, each share of which will automatically convert into 160 shares of common stock at the option of the holder or within thirty business days of the Meeting.
- [F3]The reported securities may also be deemed to be beneficially owned by Framework Ventures GP IV LLC ("Framework GP"), Framework Ventures Management LLC ("Framework Management"), Vance Spencer ("Mr. Spencer") and Michael Ernest Anderson ("Mr. Anderson" and together with Framework GP, Framework Management, Mr. Spencer and Framework LP, the "Framework Entities"), each of which or whom disclaim beneficial ownership of these shares except to the extent of its or his pecuniary interest in such shares, if any. Framework GP is the general partner of Framework LP. Framework Management is the investment manager for Framework GP. Mr. Spencer and Mr. Anderson are members and the managers of Framework GP and the managing members of Framework Management.
Issuer
NovaBay Pharmaceuticals, Inc.
CIK 0001389545
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0002091751
Filing Metadata
- Form type
- 3/A
- Filed
- Oct 21, 8:00 PM ET
- Accepted
- Oct 22, 9:22 PM ET
- Size
- 31.1 KB